Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effectiveness of statins

D M Huse1, M W Russell, J D Miller

  • 1Medical Research International/Clinical Studies, Ltd., Burlington, Massachusetts 01803-5152, USA.

The American Journal of Cardiology
|December 18, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal milk feedings reduce sepsis, necrotizing enterocolitis and improve outcomes of premature infants.

Journal of perinatology : official journal of the California Perinatal Association·2017
Same author

Preliminary Steps in the Development of an Algorithm for Identifying Relapsed CLL Patients in Secondary Data.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Packed red blood cell transfusion is not associated with increased risk of necrotizing enterocolitis in premature infants.

Journal of perinatology : official journal of the California Perinatal Association·2014
Same author

Selective use of calcium channel blockers to treat high-risk hypertensive patients.

Pharmacoepidemiology and drug safety·2008
Same author

Temporal lobe magnetic resonance spectroscopic imaging following selective amygdalohippocampectomy for treatment-resistant epilepsy.

Acta neurologica Scandinavica·2005
Same author

Randomized controlled trial of yoga and exercise in multiple sclerosis.

Neurology·2004
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Atorvastatin offers improved cost-effectiveness for preventing coronary heart disease compared to other statins. This hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor provides greater life expectancy gains at a lower cost per life-year saved.

Area of Science:

  • Pharmacoeconomics
  • Cardiovascular Disease Prevention
  • Drug Efficacy Analysis

Background:

  • Six hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are available in the US.
  • Variations in statin pricing and effectiveness necessitate cost-effectiveness analysis for optimal drug selection.

Purpose of the Study:

  • To evaluate the cost-effectiveness of statin therapy for primary and secondary prevention of coronary heart disease.
  • To compare the incremental cost-effectiveness of five statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin) against no therapy.

Main Methods:

  • A cost-consequence model was developed for lipid-regulating therapy.
  • Drug effects on serum lipids were based on US Food and Drug Administration (FDA)-approved labeling.

Related Experiment Videos

  • Coronary event risks were estimated using Framingham Heart Study equations; costs were based on current estimates of direct medical costs for coronary heart disease.

    • Main Results:

    • Atorvastatin maximized life expectancy gain and demonstrated a lower net cost than lovastatin, pravastatin, and simvastatin.
    • Compared to fluvastatin, atorvastatin achieved greater effectiveness at a lower cost per life-year saved.
    • The introduction of atorvastatin improved the cost-effectiveness of HMG-CoA reductase inhibition for coronary heart disease prevention.

    Conclusions:

    • Atorvastatin represents a more cost-effective option for coronary heart disease prevention compared to other analyzed statins.
    • Statin therapy, particularly with atorvastatin, enhances the cost-effectiveness of managing cardiovascular disease risk.
    • Cost-effectiveness analysis supports atorvastatin as a preferred choice for improving patient outcomes in coronary heart disease prevention.